Publications by authors named "J M Tallman"
Purpose: Ureteral stents are commonly placed intraoperatively during radical cystectomy, although their efficacy in reducing complications is unproven. We compared clinical outcomes among patients undergoing robot-assisted radical cystectomy with intracorporeal ileal conduit (RARC-IC) with or without ureteral stents to determine if omission of ureteral stents affects postoperative complications.
Materials And Methods: All RARC-IC surgeries performed at our institution between November 2017 and June 2023 were reviewed.
Small cell carcinomas (SMC) of the lung are now molecularly classified based on the expression of transcriptional regulators (NEUROD1, ASCL1, POU2F3, and YAP1) and DLL3, which has emerged as an investigational therapeutic target. PLCG2 has been shown to identify a distinct subpopulation of lung SMC with stem cell-like and prometastasis features and poor prognosis. We analyzed the expression of these novel neuroendocrine markers and their association with traditional neuroendocrine markers and patient outcomes in a cohort of bladder neuroendocrine carcinoma (NEC) consisting of 103 SMC and 19 large cell NEC (LCNEC) assembled in tissue microarrays.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzed outcomes of patients treated for muscle-invasive urothelial bladder cancer, identifying lymphovascular invasion (LVI) as a crucial predictor of recurrence-free survival (RFS), with patients lacking LVI showing significantly better outcomes.
- * Genomic analysis revealed chemotherapy-resistant tumors had fewer mutations in DNA damage response genes compared to chemotherapy-naïve tumors, suggesting that certain genetic markers might guide patient management.
Importance: With the ongoing bacillus Calmette-Guèrin (BCG) shortage, alternate therapeutic options for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are needed.
Objective: To report the 5-year outcomes of a cohort from a prospective phase 2 trial of patients with high-risk NMIBC who underwent 12 instillations of induction BCG without maintenance.
Design, Setting, And Participants: Between November 2015 and June 2018, patients at Memorial Sloan Kettering Cancer Center with primary or recurrent NMIBC (high-grade Ta, T1 tumors, with or without carcinoma in situ) were prospectively enrolled to receive 2 induction courses (12 intravesical instillations) of BCG without maintenance therapy.